Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms
<p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for sympt...
Ausführliche Beschreibung
Autor*in: |
Sarahi Mendoza [verfasserIn] Roberto Puente [verfasserIn] José Illnait [verfasserIn] Rosa Mas [verfasserIn] Ernesto López [verfasserIn] Daisy Carbajal [verfasserIn] Lilia Fernández [verfasserIn] Julio Fernández [verfasserIn] Meilis Mesa [verfasserIn] Pablo Reyes [verfasserIn] Dalmer Ruiz [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch ; Spanisch ; Portugiesisch |
Erschienen: |
2017 |
---|
Schlagwörter: |
D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score |
---|
Übergeordnetes Werk: |
In: Revista de la Facultad de Ciencias Médicas de Córdoba - Universidad Nacional de Córdoba, 2019, 74(2017), 2, Seite 107-118 |
---|---|
Übergeordnetes Werk: |
volume:74 ; year:2017 ; number:2 ; pages:107-118 |
Links: |
Link aufrufen |
---|
DOI / URN: |
10.31053/1853.0605.v74.n2.14479 |
---|
Katalog-ID: |
DOAJ053607759 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ053607759 | ||
003 | DE-627 | ||
005 | 20230308174724.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.31053/1853.0605.v74.n2.14479 |2 doi | |
035 | |a (DE-627)DOAJ053607759 | ||
035 | |a (DE-599)DOAJ9f4af7772b29417499bba08598098ab2 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng |a spa |a por | ||
050 | 0 | |a R5-920 | |
100 | 0 | |a Sarahi Mendoza |e verfasserin |4 aut | |
245 | 1 | 0 | |a Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a <p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4< | ||
650 | 4 | |a D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score | |
653 | 0 | |a Medicine | |
653 | 0 | |a R | |
653 | 0 | |a Medicine (General) | |
700 | 0 | |a Roberto Puente |e verfasserin |4 aut | |
700 | 0 | |a José Illnait |e verfasserin |4 aut | |
700 | 0 | |a Rosa Mas |e verfasserin |4 aut | |
700 | 0 | |a Ernesto López |e verfasserin |4 aut | |
700 | 0 | |a Daisy Carbajal |e verfasserin |4 aut | |
700 | 0 | |a Lilia Fernández |e verfasserin |4 aut | |
700 | 0 | |a Julio Fernández |e verfasserin |4 aut | |
700 | 0 | |a Meilis Mesa |e verfasserin |4 aut | |
700 | 0 | |a Pablo Reyes |e verfasserin |4 aut | |
700 | 0 | |a Dalmer Ruiz |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Revista de la Facultad de Ciencias Médicas de Córdoba |d Universidad Nacional de Córdoba, 2019 |g 74(2017), 2, Seite 107-118 |w (DE-627)688608272 |w (DE-600)2654370-9 |x 18530605 |7 nnns |
773 | 1 | 8 | |g volume:74 |g year:2017 |g number:2 |g pages:107-118 |
856 | 4 | 0 | |u https://doi.org/10.31053/1853.0605.v74.n2.14479 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/9f4af7772b29417499bba08598098ab2 |z kostenfrei |
856 | 4 | 0 | |u https://revistas.unc.edu.ar/index.php/med/article/view/14479 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/0014-6722 |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1853-0605 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 74 |j 2017 |e 2 |h 107-118 |
author_variant |
s m sm r p rp j i ji r m rm e l el d c dc l f lf j f jf m m mm p r pr d r dr |
---|---|
matchkey_str |
article:18530605:2017----::oprsnfhefccadoeaiiyfhnriipuguoaiend0bewxloosnu |
hierarchy_sort_str |
2017 |
callnumber-subject-code |
R |
publishDate |
2017 |
allfields |
10.31053/1853.0605.v74.n2.14479 doi (DE-627)DOAJ053607759 (DE-599)DOAJ9f4af7772b29417499bba08598098ab2 DE-627 ger DE-627 rakwb eng spa por R5-920 Sarahi Mendoza verfasserin aut Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4< D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score Medicine R Medicine (General) Roberto Puente verfasserin aut José Illnait verfasserin aut Rosa Mas verfasserin aut Ernesto López verfasserin aut Daisy Carbajal verfasserin aut Lilia Fernández verfasserin aut Julio Fernández verfasserin aut Meilis Mesa verfasserin aut Pablo Reyes verfasserin aut Dalmer Ruiz verfasserin aut In Revista de la Facultad de Ciencias Médicas de Córdoba Universidad Nacional de Córdoba, 2019 74(2017), 2, Seite 107-118 (DE-627)688608272 (DE-600)2654370-9 18530605 nnns volume:74 year:2017 number:2 pages:107-118 https://doi.org/10.31053/1853.0605.v74.n2.14479 kostenfrei https://doaj.org/article/9f4af7772b29417499bba08598098ab2 kostenfrei https://revistas.unc.edu.ar/index.php/med/article/view/14479 kostenfrei https://doaj.org/toc/0014-6722 Journal toc kostenfrei https://doaj.org/toc/1853-0605 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 74 2017 2 107-118 |
spelling |
10.31053/1853.0605.v74.n2.14479 doi (DE-627)DOAJ053607759 (DE-599)DOAJ9f4af7772b29417499bba08598098ab2 DE-627 ger DE-627 rakwb eng spa por R5-920 Sarahi Mendoza verfasserin aut Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4< D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score Medicine R Medicine (General) Roberto Puente verfasserin aut José Illnait verfasserin aut Rosa Mas verfasserin aut Ernesto López verfasserin aut Daisy Carbajal verfasserin aut Lilia Fernández verfasserin aut Julio Fernández verfasserin aut Meilis Mesa verfasserin aut Pablo Reyes verfasserin aut Dalmer Ruiz verfasserin aut In Revista de la Facultad de Ciencias Médicas de Córdoba Universidad Nacional de Córdoba, 2019 74(2017), 2, Seite 107-118 (DE-627)688608272 (DE-600)2654370-9 18530605 nnns volume:74 year:2017 number:2 pages:107-118 https://doi.org/10.31053/1853.0605.v74.n2.14479 kostenfrei https://doaj.org/article/9f4af7772b29417499bba08598098ab2 kostenfrei https://revistas.unc.edu.ar/index.php/med/article/view/14479 kostenfrei https://doaj.org/toc/0014-6722 Journal toc kostenfrei https://doaj.org/toc/1853-0605 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 74 2017 2 107-118 |
allfields_unstemmed |
10.31053/1853.0605.v74.n2.14479 doi (DE-627)DOAJ053607759 (DE-599)DOAJ9f4af7772b29417499bba08598098ab2 DE-627 ger DE-627 rakwb eng spa por R5-920 Sarahi Mendoza verfasserin aut Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4< D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score Medicine R Medicine (General) Roberto Puente verfasserin aut José Illnait verfasserin aut Rosa Mas verfasserin aut Ernesto López verfasserin aut Daisy Carbajal verfasserin aut Lilia Fernández verfasserin aut Julio Fernández verfasserin aut Meilis Mesa verfasserin aut Pablo Reyes verfasserin aut Dalmer Ruiz verfasserin aut In Revista de la Facultad de Ciencias Médicas de Córdoba Universidad Nacional de Córdoba, 2019 74(2017), 2, Seite 107-118 (DE-627)688608272 (DE-600)2654370-9 18530605 nnns volume:74 year:2017 number:2 pages:107-118 https://doi.org/10.31053/1853.0605.v74.n2.14479 kostenfrei https://doaj.org/article/9f4af7772b29417499bba08598098ab2 kostenfrei https://revistas.unc.edu.ar/index.php/med/article/view/14479 kostenfrei https://doaj.org/toc/0014-6722 Journal toc kostenfrei https://doaj.org/toc/1853-0605 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 74 2017 2 107-118 |
allfieldsGer |
10.31053/1853.0605.v74.n2.14479 doi (DE-627)DOAJ053607759 (DE-599)DOAJ9f4af7772b29417499bba08598098ab2 DE-627 ger DE-627 rakwb eng spa por R5-920 Sarahi Mendoza verfasserin aut Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4< D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score Medicine R Medicine (General) Roberto Puente verfasserin aut José Illnait verfasserin aut Rosa Mas verfasserin aut Ernesto López verfasserin aut Daisy Carbajal verfasserin aut Lilia Fernández verfasserin aut Julio Fernández verfasserin aut Meilis Mesa verfasserin aut Pablo Reyes verfasserin aut Dalmer Ruiz verfasserin aut In Revista de la Facultad de Ciencias Médicas de Córdoba Universidad Nacional de Córdoba, 2019 74(2017), 2, Seite 107-118 (DE-627)688608272 (DE-600)2654370-9 18530605 nnns volume:74 year:2017 number:2 pages:107-118 https://doi.org/10.31053/1853.0605.v74.n2.14479 kostenfrei https://doaj.org/article/9f4af7772b29417499bba08598098ab2 kostenfrei https://revistas.unc.edu.ar/index.php/med/article/view/14479 kostenfrei https://doaj.org/toc/0014-6722 Journal toc kostenfrei https://doaj.org/toc/1853-0605 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 74 2017 2 107-118 |
allfieldsSound |
10.31053/1853.0605.v74.n2.14479 doi (DE-627)DOAJ053607759 (DE-599)DOAJ9f4af7772b29417499bba08598098ab2 DE-627 ger DE-627 rakwb eng spa por R5-920 Sarahi Mendoza verfasserin aut Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4< D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score Medicine R Medicine (General) Roberto Puente verfasserin aut José Illnait verfasserin aut Rosa Mas verfasserin aut Ernesto López verfasserin aut Daisy Carbajal verfasserin aut Lilia Fernández verfasserin aut Julio Fernández verfasserin aut Meilis Mesa verfasserin aut Pablo Reyes verfasserin aut Dalmer Ruiz verfasserin aut In Revista de la Facultad de Ciencias Médicas de Córdoba Universidad Nacional de Córdoba, 2019 74(2017), 2, Seite 107-118 (DE-627)688608272 (DE-600)2654370-9 18530605 nnns volume:74 year:2017 number:2 pages:107-118 https://doi.org/10.31053/1853.0605.v74.n2.14479 kostenfrei https://doaj.org/article/9f4af7772b29417499bba08598098ab2 kostenfrei https://revistas.unc.edu.ar/index.php/med/article/view/14479 kostenfrei https://doaj.org/toc/0014-6722 Journal toc kostenfrei https://doaj.org/toc/1853-0605 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 74 2017 2 107-118 |
language |
English Spanish Portuguese |
source |
In Revista de la Facultad de Ciencias Médicas de Córdoba 74(2017), 2, Seite 107-118 volume:74 year:2017 number:2 pages:107-118 |
sourceStr |
In Revista de la Facultad de Ciencias Médicas de Córdoba 74(2017), 2, Seite 107-118 volume:74 year:2017 number:2 pages:107-118 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score Medicine R Medicine (General) |
isfreeaccess_bool |
true |
container_title |
Revista de la Facultad de Ciencias Médicas de Córdoba |
authorswithroles_txt_mv |
Sarahi Mendoza @@aut@@ Roberto Puente @@aut@@ José Illnait @@aut@@ Rosa Mas @@aut@@ Ernesto López @@aut@@ Daisy Carbajal @@aut@@ Lilia Fernández @@aut@@ Julio Fernández @@aut@@ Meilis Mesa @@aut@@ Pablo Reyes @@aut@@ Dalmer Ruiz @@aut@@ |
publishDateDaySort_date |
2017-01-01T00:00:00Z |
hierarchy_top_id |
688608272 |
id |
DOAJ053607759 |
language_de |
englisch spanisch portugiesisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ053607759</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308174724.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.31053/1853.0605.v74.n2.14479</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ053607759</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9f4af7772b29417499bba08598098ab2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">spa</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Sarahi Mendoza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Roberto Puente</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">José Illnait</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rosa Mas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ernesto López</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daisy Carbajal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lilia Fernández</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Julio Fernández</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Meilis Mesa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pablo Reyes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dalmer Ruiz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Revista de la Facultad de Ciencias Médicas de Córdoba</subfield><subfield code="d">Universidad Nacional de Córdoba, 2019</subfield><subfield code="g">74(2017), 2, Seite 107-118</subfield><subfield code="w">(DE-627)688608272</subfield><subfield code="w">(DE-600)2654370-9</subfield><subfield code="x">18530605</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:74</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:107-118</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.31053/1853.0605.v74.n2.14479</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9f4af7772b29417499bba08598098ab2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://revistas.unc.edu.ar/index.php/med/article/view/14479</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0014-6722</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1853-0605</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">74</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">107-118</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Sarahi Mendoza |
spellingShingle |
Sarahi Mendoza misc R5-920 misc D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score misc Medicine misc R misc Medicine (General) Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms |
authorStr |
Sarahi Mendoza |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)688608272 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
R5-920 |
illustrated |
Not Illustrated |
issn |
18530605 |
topic_title |
R5-920 Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score |
topic |
misc R5-920 misc D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score misc Medicine misc R misc Medicine (General) |
topic_unstemmed |
misc R5-920 misc D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score misc Medicine misc R misc Medicine (General) |
topic_browse |
misc R5-920 misc D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score misc Medicine misc R misc Medicine (General) |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Revista de la Facultad de Ciencias Médicas de Córdoba |
hierarchy_parent_id |
688608272 |
hierarchy_top_title |
Revista de la Facultad de Ciencias Médicas de Córdoba |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)688608272 (DE-600)2654370-9 |
title |
Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms |
ctrlnum |
(DE-627)DOAJ053607759 (DE-599)DOAJ9f4af7772b29417499bba08598098ab2 |
title_full |
Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms |
author_sort |
Sarahi Mendoza |
journal |
Revista de la Facultad de Ciencias Médicas de Córdoba |
journalStr |
Revista de la Facultad de Ciencias Médicas de Córdoba |
callnumber-first-code |
R |
lang_code |
eng spa por |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2017 |
contenttype_str_mv |
txt |
container_start_page |
107 |
author_browse |
Sarahi Mendoza Roberto Puente José Illnait Rosa Mas Ernesto López Daisy Carbajal Lilia Fernández Julio Fernández Meilis Mesa Pablo Reyes Dalmer Ruiz |
container_volume |
74 |
class |
R5-920 |
format_se |
Elektronische Aufsätze |
author-letter |
Sarahi Mendoza |
doi_str_mv |
10.31053/1853.0605.v74.n2.14479 |
author2-role |
verfasserin |
title_sort |
comparison of the efficacy and tolerability of chondroitin plus glucosamine and d-002 (beeswax alcohols) in subjects with osteoarthritis symptoms |
callnumber |
R5-920 |
title_auth |
Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms |
abstract |
<p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4< |
abstractGer |
<p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4< |
abstract_unstemmed |
<p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4< |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
2 |
title_short |
Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms |
url |
https://doi.org/10.31053/1853.0605.v74.n2.14479 https://doaj.org/article/9f4af7772b29417499bba08598098ab2 https://revistas.unc.edu.ar/index.php/med/article/view/14479 https://doaj.org/toc/0014-6722 https://doaj.org/toc/1853-0605 |
remote_bool |
true |
author2 |
Roberto Puente José Illnait Rosa Mas Ernesto López Daisy Carbajal Lilia Fernández Julio Fernández Meilis Mesa Pablo Reyes Dalmer Ruiz |
author2Str |
Roberto Puente José Illnait Rosa Mas Ernesto López Daisy Carbajal Lilia Fernández Julio Fernández Meilis Mesa Pablo Reyes Dalmer Ruiz |
ppnlink |
688608272 |
callnumber-subject |
R - General Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.31053/1853.0605.v74.n2.14479 |
callnumber-a |
R5-920 |
up_date |
2024-07-03T18:36:03.186Z |
_version_ |
1803584026117668864 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ053607759</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308174724.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.31053/1853.0605.v74.n2.14479</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ053607759</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9f4af7772b29417499bba08598098ab2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">spa</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Sarahi Mendoza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Roberto Puente</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">José Illnait</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rosa Mas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ernesto López</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daisy Carbajal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lilia Fernández</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Julio Fernández</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Meilis Mesa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pablo Reyes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dalmer Ruiz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Revista de la Facultad de Ciencias Médicas de Córdoba</subfield><subfield code="d">Universidad Nacional de Córdoba, 2019</subfield><subfield code="g">74(2017), 2, Seite 107-118</subfield><subfield code="w">(DE-627)688608272</subfield><subfield code="w">(DE-600)2654370-9</subfield><subfield code="x">18530605</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:74</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:107-118</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.31053/1853.0605.v74.n2.14479</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9f4af7772b29417499bba08598098ab2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://revistas.unc.edu.ar/index.php/med/article/view/14479</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0014-6722</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1853-0605</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">74</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">107-118</subfield></datafield></record></collection>
|
score |
7.399583 |